REGULATORY

Drugs Being Delivered to Quake-Hit Areas Day after Request: Minister

January 10, 2024

Japan has been able to secure the next-day delivery of pharmaceuticals in central Japan areas struck by a powerful New Year’s Day earthquake, albeit depending on road conditions, Health Minister Keizo Takemi said on January 9.

The quake mainly battered Ishikawa Prefecture’s Noto Peninsula on the Sea of Japan coast. Speaking in a regular press conference, Mr Takemi explained that there are two routes to take requests for drug supplies to the region: 1) the Ishikawa prefectural government receives requests from medical institutions and then contacts local wholesalers, and 2) medical institutions directly send requests to wholesalers.

Requests not only include acute-care medicines needed immediately after the disaster, such as antimicrobials to treat trauma, but also insulin therapies for diabetes, among other treatments, the minister said.

“We have basically been able to distribute these medicines to local medical institutions the day after (the request), although it depends on road conditions,” he said.

On January 7, a mobile pharmacy vehicle reached the northern part of the peninsula called Oku-Noto, and it is now primarily operating in the city of Suzu. He said one more such vehicle will be added on January 9, which will mainly operate in the city of Wajima. “We’ll be dispatching more vehicles once local situations are confirmed,” he said.

REGULATORY

By Ken Yoshino

Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…

By Philip Carrigan

Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…

By Kohei Hori

Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…

By Kohei Hori

Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…

By Takashi Ebisawa

Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…